Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet (R)/Dovobet (R)/Taclonex (R)) in the treatment of psoriasis vulgaris

Kragballe, K. ; Austad, J. ; Barnes, L. ; Bibby, A. ; de la Brassinne, M. ; Cambazard, F. ; Fleming, C. ; Heikkila, H. ; Williams, Z. and Rey, J. Peyri , et al. (2006) In Dermatology 213(4). p.319-326
Abstract
Background: The calcipotriol/betamethasone dipropionate two-compound product is safe and effective in the short-term treatment of psoriasis. Objective: The primary objective was to investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks. The efficacy results are presented here. Methods: Six hundred and thirty-four patients were randomised double-blind to treatment (once daily, when required) with either: 52 weeks of two-compound product (two-compound group), 52 weeks of alternating 4-week periods of two-compound product and calcipotriol (alternating group), or 4 weeks of two-compound product followed by 48 weeks of calcipotriol (calcipotriol group). Results: There was a trend towards a... (More)
Background: The calcipotriol/betamethasone dipropionate two-compound product is safe and effective in the short-term treatment of psoriasis. Objective: The primary objective was to investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks. The efficacy results are presented here. Methods: Six hundred and thirty-four patients were randomised double-blind to treatment (once daily, when required) with either: 52 weeks of two-compound product (two-compound group), 52 weeks of alternating 4-week periods of two-compound product and calcipotriol (alternating group), or 4 weeks of two-compound product followed by 48 weeks of calcipotriol (calcipotriol group). Results: There was a trend towards a difference between treatments from the overall treatment effect for the percentage of satisfactory responses for each patient during the study (p = 0.071). This appeared to be due to the comparison of the two-compound and calcipotriol groups (p = 0.025). Conclusion: There was a trend towards the efficacy of the two-compound product used for up to 52 weeks being better than that of 4 weeks of the two-compound product followed by 48 weeks of calcipotriol. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Taclonex (R), Dovobet (R), Daivobet (R), psoriasis, two-compound product
in
Dermatology
volume
213
issue
4
pages
319 - 326
publisher
Karger
external identifiers
  • wos:000242372000009
  • scopus:33751532623
  • pmid:17135738
ISSN
1421-9832
DOI
10.1159/000096069
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pediatrics/Urology/Gynecology/Endocrinology (013240400)
id
49f15a71-98d5-4075-be8f-89930116a009 (old id 685631)
date added to LUP
2016-04-01 11:59:01
date last changed
2020-10-07 02:24:51
@article{49f15a71-98d5-4075-be8f-89930116a009,
  abstract     = {Background: The calcipotriol/betamethasone dipropionate two-compound product is safe and effective in the short-term treatment of psoriasis. Objective: The primary objective was to investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks. The efficacy results are presented here. Methods: Six hundred and thirty-four patients were randomised double-blind to treatment (once daily, when required) with either: 52 weeks of two-compound product (two-compound group), 52 weeks of alternating 4-week periods of two-compound product and calcipotriol (alternating group), or 4 weeks of two-compound product followed by 48 weeks of calcipotriol (calcipotriol group). Results: There was a trend towards a difference between treatments from the overall treatment effect for the percentage of satisfactory responses for each patient during the study (p = 0.071). This appeared to be due to the comparison of the two-compound and calcipotriol groups (p = 0.025). Conclusion: There was a trend towards the efficacy of the two-compound product used for up to 52 weeks being better than that of 4 weeks of the two-compound product followed by 48 weeks of calcipotriol.},
  author       = {Kragballe, K. and Austad, J. and Barnes, L. and Bibby, A. and de la Brassinne, M. and Cambazard, F. and Fleming, C. and Heikkila, H. and Williams, Z. and Rey, J. Peyri and Svensson, Åke and Toole, J. and Wozel, G.},
  issn         = {1421-9832},
  language     = {eng},
  number       = {4},
  pages        = {319--326},
  publisher    = {Karger},
  series       = {Dermatology},
  title        = {Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet (R)/Dovobet (R)/Taclonex (R)) in the treatment of psoriasis vulgaris},
  url          = {http://dx.doi.org/10.1159/000096069},
  doi          = {10.1159/000096069},
  volume       = {213},
  year         = {2006},
}